Details for Patent: 5,736,124
✉ Email this page to a colleague
| Title: | Aerosol formulations containing P134a and particulate medicament |
| Abstract: | This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described. |
| Inventor(s): | Akehurst; Rachel Ann (Ware, GB3), Taylor; Anthony James (Ware, GB3), Wyatt; David Andrew (Ware, GB3) |
| Assignee: | Glaxo Group Limited (London, GB2) |
| Filing Date: | May 30, 1995 |
| Application Number: | 08/453,820 |
| Claims: | 1. A pharmaceutical aerosol formulation consisting essentially of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) 0.01 to 5% w/w based upon the propellent of a polar cosolvent which is a C.sub.2-5 aliphatic alcohol or polyol or a mixture thereof, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament. 2. A formulation as claimed in claim 1, wherein the polar cosolvent is present in an amount from 0.05 to 3% w/w based upon the propellant. 3. A formulation as claimed in claim 2, wherein said medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid. 4. A formulation as claimed in claim 2 wherein said medicament is selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof. 5. A formulation as claimed in claim 2 wherein said medicament is beclomethasone dipropionate or a physiologically acceptable solvate thereof. 6. A formulation as claimed in claim 2 wherein said medicament is selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol rimiterol, terbutaline, isoetharine, tolubuterol, orciprenaline, (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino] methyl]benzene-methanol and physiologically acceptable salts thereof. 7. A formulation as claimed in claim 2 which contains two or more particulate medicaments. 8. A formulation as claimed in claim 2 which contains a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament. 9. A formulation as claimed in claim 2 which contains salmeterol xinafoate in combination with fluticasone propionate. 10. A formulation as claimed in claim 2 which is free of surfactant. 11. A formulation as claimed in claim 2 wherein the polar cosolvent is ethanol. 12. A formulation as claimed in claim 2 wherein the medicament is present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation. 13. A formulation as claimed in claim 2 which has a respirable fraction of 20% or more by weight of the medicament. 14. A pharmaceutical aerosol formulation consisting of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent which is C.sub.2-5 aliphatic alcohol or polyol or a mixture thereof, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns. 15. A formulation as claimed in claim 14 wherein the polar cosolvent is present in an amount from 0.05 to 3% w/w based upon the propellant. 16. A formulation as claimed in claim 15 wherein said medicament is selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solyates thereof. 17. A formulation as claimed in claim 15 wherein said medicament is beclomethasone dipropionate or a physiologically acceptable solvate thereof. 18. A formulation as claimed in claim 15 wherein said medicament is selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline, (-)-4-amino-3,5-dichloro-.alpha.-[[[6-[2-2(pyridinyl)ethoxy]hexyl]-amino]m ethyl]benzene-methanol and physiologically acceptable salts thereof. 19. A formulation as claimed in claim 15 which contains two or more particulate medicaments. 20. A formulation as claimed in claim 15 which contains a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament. 21. A formulation as claimed in claim 15 which contains salmeterol xinafoate in combination with fluticasone propionate. 22. A formulation as claimed in claim 15 wherein said medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid. 23. A formulation as claimed in claim 15 wherein the polar cosolvent is ethanol. 24. A formulation as claimed in claim 15 wherein the medicament is present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation. 25. A formulation as claimed in claim 15 which has a respirable fraction of 20% or more by weight of the medicament. 26. A formulation as claimed in claim 2 wherein the polar cosolvent is ethanol. 27. A formulation as claimed in claim 22 wherein the polar cosolvent is ethanol. 28. A pharmaceutical aerosol formulation consisting essentially of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant and (iii) 0.05 to 5% w/w based upon the propellant of a polar cosolvent being ethanol, isopropanol, propylene glycol or a mixture thereof, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament. 29. A formulation as claimed in claim 28 which is free of surfactant. 30. A formulation as claimed in claim 28 which contains 0.05 to 3% w/w based upon the propellant of a polar cosolvent. 31. A formulation as claimed in claim 29 which contains 0.05 to 3% w/w based upon the propellant of a polar cosolvent. 32. A formulation as claimed in claim 28 wherein the polar cosolvent is ethanol. 33. A formulation as claimed in claim 29 wherein the polar cosolvent is ethanol. 34. A formulation as claimed in claim 28 wherein said medicament is formoterol. 35. A formulation as claimed in claim 29 wherein said medicament is formoterol. 36. A pharmaceutical aerosol formulation consisting of (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane as propellant and (iii) 0.05 to 5% w/w based upon the propellant of a polar cosolvent being ethanol, isopropanol, propylene glycol or a mixture thereof, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns. 37. A formulation as claimed in claim 36 which contains 0.05 to 3% w/w based upon the propellant of a polar cosolvent. 38. A formulation as claimed in claim 36 wherein the polar cosolvent is ethanol. 39. A formulation as claimed in claim 1 wherein the polar cosolvent is present in an amount of 0.05 to 5% w/w based upon the propellant. 40. A pharmaceutical aerosol formulation consisting of (i) a particulate medicament which is salmeterol or physiologically acceptable salts thereof, (ii) 1,1,1,2-tetrafluoroethane as propellant and (iii) 0.05 to 5% w/w based upon the propellant of a polar cosolvent being ethanol, isopropanol, propylene glycol or a mixture thereof, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns. 41. A formulation as claimed in claim 40 wherein the polar cosolvent is ethanol. 42. A formulation as claimed in claim 40 wherein the salmeterol is in the form of salmeterol xinafoate. 43. A formulation as claimed in claim 42 wherein the polar cosolvent is ethanol. |
